OMER
Omeros Corporation · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website omeros.com
- Employees(FY) 196
- ISIN US6821431029
Performance
-11.8%
1W
+139.0%
1M
+197.74%
3M
+173.06%
6M
+222.32%
YTD
+318.25%
1Y
Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Technical Analysis of OMER 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 19:45
- 2024-12-02 08:45
- 2024-12-01 19:45
- 2024-11-22 14:31
- 2024-11-21 09:15
- 2024-11-20 20:15
- 2024-11-14 01:01
Q3 2024 Omeros Corp Earnings Call(Yahoo Finance)
- 2024-11-13 16:02
- 2024-11-13 13:15
- 2024-11-13 03:17
Omeros: Q3 Earnings Snapshot(Yahoo Finance)
- 2024-11-13 03:02
- 2024-11-11 16:11
- 2024-11-11 03:11
- 2024-10-24 10:36
- 2024-10-23 20:45
- 2024-08-07 05:16
Omeros: Q2 Earnings Snapshot(Yahoo Finance)
- 2024-08-07 04:02
- 2024-08-05 04:02
- 2024-06-03 21:00
- 2024-06-02 21:00
- 2024-05-16 01:10
Q1 2024 Omeros Corp Earnings Call(Yahoo Finance)
- 2024-05-15 15:10
- 2024-05-15 08:55
OMER Stock Earnings: Omeros Misses EPS for Q1 2024(Investorplace)
- 2024-05-15 04:11
Omeros: Q1 Earnings Snapshot(Yahoo Finance)
- 2024-05-15 04:02
- 2024-05-09 20:50
- 2024-05-08 20:50
- 2024-04-02 00:41
Q4 2023 Omeros Corp Earnings Call(Yahoo Finance)
- 2024-04-01 23:22
- 2024-04-01 09:53
OMER Stock Earnings: Omeros Misses EPS for Q4 2023(Investorplace)
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.